Predictors of Survival in Melanoma
Author Information
Author(s): A Franzke, M Probst-Kepper, J Buer, S Duensing, R Hoffmann, F Wittke, M Volkenandt, A Ganser, J Atzpodien
Primary Institution: Medizinische Hochschule Hanover
Hypothesis
Can elevated serum levels of soluble adhesion molecules predict survival in patients with metastatic cutaneous malignant melanoma?
Conclusion
Elevated pretreatment serum levels of sVCAM-1 and lactate dehydrogenase correlate with poor outcomes in patients with metastatic cutaneous malignant melanoma.
Supporting Evidence
- Patients with elevated sVCAM-1 had a median survival of 5 months.
- Patients with normal sVCAM-1 levels had a median survival of 12 months.
- Elevated LDH levels were associated with a median survival of 5 months compared to 16 months for normal levels.
Takeaway
Doctors can tell how long someone might live with melanoma by looking at certain blood tests. If the tests show high levels of specific proteins, it might mean the person won't live as long.
Methodology
The study evaluated serum levels of soluble adhesion molecules and clinical parameters in relation to overall survival using univariate and multivariate Cox proportional-hazards models.
Limitations
The study's model needs to be validated in prospective trials.
Participant Demographics
{"sex":{"male":61,"female":36},"age":{"mean":52.2,"range":"20-73"}}
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website